Medical University of Vienna, Department of Internal Medicine III
Welcome,         Profile    Billing    Logout  
 16 Trials 
10 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trauner, Michael
COMBAT_T2_NASH, NCT04639414: Combined Active Treatment in Type 2 Diabetes With NASH

Recruiting
4
192
Europe
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo
The Deutsche Diabetes Forschungsgesellschaft e.V., Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S
Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
01/25
12/25
NCT03872921: norUrsodeoxycholic Acid vs Placebo in PSC

Recruiting
3
300
Europe
norUrsodeoxycholic Acid, NUC
Dr. Falk Pharma GmbH
Primary Sclerosing Cholangitis
04/21
12/23
NCT04594694 / 2018-002575-17: Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Active, not recruiting
2
72
Europe, RoW
Obeticholic acid, Bezafibrate 200 MG, OCA Placebo, Bezafibrate 200 mg Placebo, Bezafibrate 400 MG, Bezafibrate 400 mg Placebo, OCA, Bezafibrate
Intercept Pharmaceuticals
Primary Biliary Cholangitis
10/25
12/25
NCT05083390 / 2018-003443-31: Norursodeoxycholic Acid vs. Placebo in NASH

Recruiting
2
363
Europe
norUrsodeoxycholic acid, norucholic acid, norUDCA, NCA
Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH,
Nonalcoholic Steatohepatitis
01/25
04/25
Ludvik, Bernhard
COMBAT_T2_NASH, NCT04639414: Combined Active Treatment in Type 2 Diabetes With NASH

Recruiting
4
192
Europe
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo
The Deutsche Diabetes Forschungsgesellschaft e.V., Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S
Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
01/25
12/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight and Obesity
02/29
02/29
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Recruiting
3
2620
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
04/25
12/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
TREASURE-CKD, NCT05536804 / 2021-005273-47: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
140
Europe, Canada, US, RoW
Tirzepatide, Placebo
Eli Lilly and Company, Eli Lilly and Company
Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
01/26
02/26
Krebs, Michael
No trials found
Scherer, Thomas
No trials found
Krssak, Martin
No trials found
Winhofer, Yvonne
No trials found

Download Options